Clinical trials: sponsored by Eli Lilly and Company
Diabetes Type 2, Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes
The main purpose of this study is to compare the effect of the addition of tirzepatide or placebo to titrated basal insulin on glycemic control in Chinese participants with type 2 diabetes.
- Conditions
- Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease
- Trial name
- SURPASS-CN-INS (NCT05691712)
- Testing
- Tirzepatide
- Where
- 25 sites in China
- Volunteers
- 257 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteers
Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers
Phase 1a randomized, double-blind, placebo-controlled study to evaluate single and multiple ascending doses of MORF-057 in healthy subjects.
- Trial name
- NCT04580745
- Testing
- MORF-057
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Healthy
A Study of the Absorption, Distribution, Metabolism and Excretion of LY3039478 in Healthy Participants
This type of study is called a radiolabeled study. For this study, LY3039478 (study drug) has been specially prepared to contain radiolabeled carbon [¹⁴C]. [¹⁴C] is a naturally occurring radioactive form of the element carbon.
- Trial name
- NCT02917733
- Testing
- LY3039478
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
Study of LY3039478 in Healthy Participants
The study involves one dose of LY3039478 given by mouth followed by an intravenous infusion (IV) (via a tube linked to a small needle in the vein) of LY3039478.
- Trial name
- NCT02906618
- Testing
- LY3039478, 13C 15N 2H-LY3039478 IV
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Overweight, Healthy
A Study of LY3541105 in Healthy and Overweight Participants
The main purpose of this study is to evaluate the safety and tolerability of LY3541105 in healthy and overweight participants. Blood tests will be performed to check how much LY3541105 gets into the bloodstream and how long it…
- Trial name
- NCT05380323
- Testing
- LY3541105
- Where
- 2 sites in United States
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants
The main purpose of this study is to assess and compare a single capsule and multiple capsules of Orforglipron based on the amount that gets into the blood stream and how long it takes the body to get rid of it, when given to…
- Trial name
- NCT06692348
- Testing
- Orforglipron
- Where
- 3 sites in Japan
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A First-In-Human Study of LY3839840 in Healthy Participants
The main purpose of this first-in-human study to investigate the safety of LY3839840 in single and multiple doses, and how it's processed in the body when given in different amounts.
- Trial name
- NCT06153355
- Testing
- LY3839840, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants
The purpose of this study J1I-MC-GZQE is to measure the effect of retatrutide on the pharmacokinetics (PK) of metoprolol in healthy participants.
- Trial name
- NCT06808802
- Testing
- Retatrutide, Metoprolol
- Where
- Singapore
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hypertriglyceridemia
A Study of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia
The main purpose of this study is to determine the tolerability and side effects related to LY3875383 given as a single injection under the skin to healthy participants and participants with elevated triglyceride (TG) levels.The…
- Trial name
- NCT05609825
- Testing
- LY3875383
- Where
- Singapore
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of LY4064809 [14C]-STX-478 in Healthy Male Participants
The main purpose of this study is to conduct blood tests to measure how much STX-478 is in the bloodstream and how the body handles and eliminates it in healthy participants.
- Trial name
- NCT06901336
- Testing
- [14C]-STX-478
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company
Healthy
A Study of Selpercatinib (LY3527723) in Healthy Participants
The main purpose of this study is to determine how safe and how well tolerated selpercatinib is when given as oral doses to healthy participants.
- Trial name
- NCT05338515
- Testing
- Selpercatinib
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of LY3873862 in Healthy Participants
The main purpose of this study is to evaluate the safety and tolerability of LY3873862 when administered either in single or multiple doses in healthy participants.
- Trial name
- NCT05492201
- Testing
- LY3873862
- Where
- United Kingdom
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteers
Mass Balance and Pharmacokinetics (PK) of [14C]-DC-806 in Healthy Male Participants
The primary objective of this study is to investigate the rate and routes of excretion, including the mass balance, after single oral dose administration of DC-806 containing 3.7 MBq (100 μCi) of [14C]-DC-806 in urine and feces.
- Trial name
- NCT06045000
- Testing
- DC-806, [14C]-DC-806
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Healthy
A Study of Tirzepatide (LY3298176) in Healthy Lactating Females
The main purpose of this study was to look if the study drug, tirzepatide, gets into the breastmilk and, if yes, how long it takes the body to get rid of it from the breastmilk.
- Trial name
- NCT05978713
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants
The main purpose of this study is to assess the effect of multiple doses of itraconazole, fluconazole, and carbamazepine on single dose pharmacokinetic of LY4100511 (DICE-853) in healthy participants.
- Trial name
- NCT06345794
- Testing
- LY4100511 (DC-853), Itraconazole, Fluconazole
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Healthy
A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants
The main purpose of this study is to compare the amount of selpercatinib that gets into the blood stream and how long it takes the body to get rid of it and also to assess the pharmacokinetics (PK), metabolism, and routes and…
- Trial name
- NCT05630287
- Testing
- [14C]-Selpercatinib, Selpercatinib
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DC-853 in Healthy Participants
The main purpose of this study is to assess the safety and tolerability of LY4100511 (DC-853) after single and multiple dose administrations in healthy participants. Participation could last up to 7 weeks
- Trial name
- NCT06937411
- Testing
- LY4100511
- Where
- United Kingdom
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy, Hepatic Insufficiency
A Study of LY3437943 in Participants With Impaired and Normal Liver Function
The main purpose of this study is to measure how much of LY3437943 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to…
- Trial name
- NCT05916560
- Testing
- LY3437943
- Where
- 5 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy, Hepatic Impairment
A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants
The main purpose of this study is to assess how selpercatinib gets into the blood stream and how long it takes the body to remove it when administered to participants with impaired hepatic function compared to healthy…
- Trial name
- NCT05436912
- Testing
- Selpercatinib
- Where
- 7 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of LY4065967 in Healthy Japanese Participants
The purpose of this study is to obtain safety and tolerability data of the study drug known as LY4065967 and rosuvastatin in healthy Japanese participants.
- Trial name
- NCT06594159
- Testing
- LY4065967, Rosuvastatin
- Where
- Japan
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company